Pharmacokinetics and selected pharmacodynamics of trazodone following intravenous and oral administration to horses undergoing fitness training

Heather K. Knych K. L. Maddy Equine Analytical Chemistry Laboratory, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616
Department of Veterinary Molecular Biosciences, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616

Search for other papers by Heather K. Knych in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Khursheed R. Mama Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523.

Search for other papers by Khursheed R. Mama in
Current site
Google Scholar
PubMed
Close
 DVM
,
Eugene P. Steffey Veterinary Surgery and Radiology, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616

Search for other papers by Eugene P. Steffey in
Current site
Google Scholar
PubMed
Close
 VMD, PhD
,
Scott D. Stanley K. L. Maddy Equine Analytical Chemistry Laboratory, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616
Department of Veterinary Molecular Biosciences, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616

Search for other papers by Scott D. Stanley in
Current site
Google Scholar
PubMed
Close
 PhD
, and
Philip H. Kass Population Health and Reproduction, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616

Search for other papers by Philip H. Kass in
Current site
Google Scholar
PubMed
Close
 DVM, PhD

Abstract

OBJECTIVE To measure concentrations of trazodone and its major metabolite in plasma and urine after administration to healthy horses and concurrently assess selected physiologic and behavioral effects of the drug.

ANIMALS 11 Thoroughbred horses enrolled in a fitness training program.

PROCEDURES In a pilot investigation, 4 horses received trazodone IV (n = 2) or orally (2) to select a dose for the full study; 1 horse received a vehicle control treatment IV. For the full study, trazodone was initially administered IV (1.5 mg/kg) to 6 horses and subsequently given orally (4 mg/kg), with a 5-week washout period between treatments. Blood and urine samples were collected prior to drug administration and at multiple time points up to 48 hours afterward. Samples were analyzed for trazodone and metabolite concentrations, and pharmacokinetic parameters were determined; plasma drug concentrations following IV administration best fit a 3-compartment model. Behavioral and physiologic effects were assessed.

RESULTS After IV administration, total clearance of trazodone was 6.85 ± 2.80 mL/min/kg, volume of distribution at steady state was 1.06 ± 0.07 L/kg, and elimination half-life was 8.58 ± 1.88 hours. Terminal phase half-life was 7.11 ± 1.70 hours after oral administration. Horses had signs of aggression and excitation, tremors, and ataxia at the highest IV dose (2 mg/kg) in the pilot investigation. After IV drug administration in the full study (1.5 mg/kg), horses were ataxic and had tremors; sedation was evident after oral administration.

CONCLUSIONS AND CLINICAL RELEVANCE Administration of trazodone to horses elicited a wide range of effects. Additional study is warranted before clinical use of trazodone in horses can be recommended.

Abstract

OBJECTIVE To measure concentrations of trazodone and its major metabolite in plasma and urine after administration to healthy horses and concurrently assess selected physiologic and behavioral effects of the drug.

ANIMALS 11 Thoroughbred horses enrolled in a fitness training program.

PROCEDURES In a pilot investigation, 4 horses received trazodone IV (n = 2) or orally (2) to select a dose for the full study; 1 horse received a vehicle control treatment IV. For the full study, trazodone was initially administered IV (1.5 mg/kg) to 6 horses and subsequently given orally (4 mg/kg), with a 5-week washout period between treatments. Blood and urine samples were collected prior to drug administration and at multiple time points up to 48 hours afterward. Samples were analyzed for trazodone and metabolite concentrations, and pharmacokinetic parameters were determined; plasma drug concentrations following IV administration best fit a 3-compartment model. Behavioral and physiologic effects were assessed.

RESULTS After IV administration, total clearance of trazodone was 6.85 ± 2.80 mL/min/kg, volume of distribution at steady state was 1.06 ± 0.07 L/kg, and elimination half-life was 8.58 ± 1.88 hours. Terminal phase half-life was 7.11 ± 1.70 hours after oral administration. Horses had signs of aggression and excitation, tremors, and ataxia at the highest IV dose (2 mg/kg) in the pilot investigation. After IV drug administration in the full study (1.5 mg/kg), horses were ataxic and had tremors; sedation was evident after oral administration.

CONCLUSIONS AND CLINICAL RELEVANCE Administration of trazodone to horses elicited a wide range of effects. Additional study is warranted before clinical use of trazodone in horses can be recommended.

Contributor Notes

Address correspondence to Dr. Knych (hkknych@ucdavis.edu).
  • 1. Frazer A, Hensler JG. Serotonin. In: Siegel GJ, Agranoff BW, Albers RW, et al, eds. Basic neurochemistry. 6th ed. Philadelphia: Lippincott-Raven, 1999; 263292.

    • Search Google Scholar
    • Export Citation
  • 2. Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr 2009; 14: 536546.

  • 3. Haria M, Fitton A, McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging 1994; 4: 331355.

    • Search Google Scholar
    • Export Citation
  • 4. Mittur A. Trazodone: properties and utility in multiple disorders. Expert Rev Clin Pharmacol 2011; 4: 181196.

  • 5. Bossini L, Casolaro I, Koukouna D, et al. Off label uses of trazodone: a review. Expert Rev Clin Pharmacol 2012; 13: 17071717.

  • 6. Rotzinger S, Fang J, Baker GB. Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos 1998; 26: 572575.

    • Search Google Scholar
    • Export Citation
  • 7. Wen B, Ma L, Rodrigues D, et al. Detection of novel reactive metabolites of trazodone: evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine. Drug Metab Dispos 2008; 36: 841850.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8. Gruen ME, Sherman BL. Use of trazodone as an adjunctive agent in the treatment of canine anxiety disorders: 56 cases (1997–2007). J Am Vet Med Assoc 2008; 233: 19021907.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9. Jay AR, Krotscheck U, Parsley E, et al. Pharmacokinetics, bioavailability, and hemodynamic effects of trazodone after intravenous and oral administration of a single dose to dogs. Am J Vet Res 2013; 74: 14501456.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10. Knych HK, Arthur RM, Mitchell MM, et al. Pharmacokinetics and selected pharmacodynamics of cobalt following a single intravenous administration to horses. Drug Test Anal 2015; 7: 619625.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978; 6: 165175.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12. Mama KR, Grimsrud K, Snell T, et al. Plasma concentrations, behavioural and physiological effects following intravenous and intramuscular detomidine in horses. Equine Vet J 2009; 41: 772777.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13. Gruen ME, Roe SC, Griffith E, et al. The use of trazodone to facilitate postsurgical confinement in dogs. J Am Vet Med Assoc 2014; 245: 296301.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14. Orlando JM, Case BC, Thomson AE, et al. Use of oral trazodone for sedation in cats: a pilot study. J Feline Med Surg 2016; 18: 476482.

  • 15. Kale P, Agrawal YK. Pharmacokinetics of single oral dose trazodone: a randomized, two-period, cross-over trial in healthy, adult, human volunteers under fed condition. Front Pharmacol 2015; 6: 224.

    • Search Google Scholar
    • Export Citation
  • 16. Nilsen OG, Dale O. Single dose pharmacokinetics of trazodone in healthy subjects. Pharmacol Toxicol 1992; 71: 150153.

  • 17. Vatassery GT, Holden LA, Hazel DK, et al. Determination of trazodone and its metabolite, 1-m-chlorophenyl-piperzine, in human plasma and red blood cell samples by HPLC. Clin Biochem 1997; 30: 149153.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18. Mercolini L, Colliva C, Amore M, et al. HPLC analysis of the antidepressant trazodone and its main metabolite mCPP in human plasma. J Pharm Biomed Anal 2008; 47: 882887.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities and impact of genetic variation. Pharmacol Ther 2013; 138: 103141.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20. Corado CR. McKemie, Young A, Knych HK. Evidence for polymorphism in the cytochrome P450 2D6 gene in horses. J Vet Pharmacol Ther 2016; 39: 245254.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 21. Corado CR. McKemie, Knych HK. Dextromethorphan and debrisoquine metabolism and polymorphism of the gene for cytochrome P450 isozyme 2D50 in Thoroughbreds. Am J Vet Res 2016; 77: 10291035.

    • Crossref
    • Search Google Scholar
    • Export Citation

Advertisement